Evaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma

Basit Öğe Kaydı
dc.contributor.authorEbinc, Senar
dc.contributor.authorKalkan, Ziya
dc.contributor.authorOruc, Zeynep
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorIsikdogan, Abdurrahman
dc.date.accessioned2024-04-24T17:27:57Z
dc.date.available2024-04-24T17:27:57Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction. It is known that sunitinib and pazopanib are effective in the first-line and subsequent treatment of metastatic renal cell carcinoma (mRCC). This study aims to investigate the effectiveness and tolerability of sunitinib and pazopanib in the first-line treatment of mRCC. Material and metbods. This study included 78 patients followed up in our clinic due to a diagnosis of mRCC, who received pazopanib or sunitinib treatment between 2006 and 2020. Along with clinical and laboratory findings, survival times obtained with each treatment and medication side effects were assessed. Sunitinib and pazopanib were compared in terms of effectiveness (ORR, PFS and OS) and tolerability. Results. The patients' median age at diagnosis was 55 years (25-81). In the first-line treatment, 54 patients (69.2%) received sunitinib and 24 (30.8%) received pazopanib. The comparison of sunitinib and pazopanib yielded an ORR of 66.7% vs. 45.8% (p = 0.08), PFS of 24 months vs. 19 months (p = 0.66) and OS of 27 months vs. 30 months (p = 0.73), respectively. The most common side effect was hypothyroidism in those on sunitinib (25.9%) and nausea-vomiting in those on pazopanib (41.7%). In our study, hemoglobin >= 13 g/dL, an ECOG PS of 0-1 and the occurrence of hypothyroidism as a medication side effect were found to be predictive factors of PFS for both agents. An International Metastatic RCC Database Consortium score corresponding to the poor risk group was associated with a poor PFS. Conclusions. This study, which provides current real-world data, confirms that sunitinib and pazopanib have similar effectiveness and side-effect profiles in the first-line treatment of mRCC.en_US
dc.identifier.doi10.5603/OCP.2021.0033
dc.identifier.endpage234en_US
dc.identifier.issn2450-1654
dc.identifier.issn2450-6478
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85139022749
dc.identifier.scopusqualityQ4
dc.identifier.startpage226en_US
dc.identifier.urihttps://doi.org/10.5603/OCP.2021.0033
dc.identifier.urihttps://hdl.handle.net/11468/20267
dc.identifier.volume18en_US
dc.identifier.wosWOS:000852644300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherVia Medicaen_US
dc.relation.ispartofOncology in Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectSunitiniben_US
dc.subjectPazopaniben_US
dc.subjectVegfr Inhibitorsen_US
dc.titleEvaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinomaen_US
dc.titleEvaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu